Akari Therapeutics
Akari Therapeutics - England to Boston Rachelle Jacques.
Former CEO, Akari Therapeutics
Search every verified Rachelle Jacques interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Rachelle Jacques, president and CEO of Akari Therapeutics, discussed the company's development of nomacopan, a recombinant protein derived from tick saliva, in a November 2022 podcast interview. She described the molecule's origins in tick saliva's anti-inflammatory properties and detailed the manufacturing challenges the company faced, including low yields from insect cell expression systems before transitioning to a microbial expression environment for higher scalability. Jacques noted that Akari is pursuing nomacopan for broader therapeutic applications beyond a single small patient population, with a focus on pediatric patients with severe HSCT-TMA, a complication following stem cell or bone marrow transplants. Jacques also spoke about her professional background, stating that she joined Akari six months prior and that her previous experience in the complement inhibition space made the role feel like "coming back home." She expressed enthusiasm for the potential of complement inhibition and highlighted Akari's lead asset as a bi-specific molecule, emphasizing the company's commitment to advancing clinical progress in this area.
Akari Therapeutics, plc (NASDAQ: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Keynote speaker: Rachelle Jacques, CEO
Ticks are a scourge. They're vectors of multiple serious an debilitating diseases, and evolution has made them perfectly adept at attaching to their hosts—and potentially spreading those diseases virtually undetected— that ability owing to anti-inflammatory and anesthetic proteins in their saliva. But the emerging biotech Akari Therapeutics thinks there's a broad range of medicinal value in those proteins. They've painstakingly developed a recombinant version of one such tick saliva-derived protein, called nomacopan, and put it to work in phase 3 trials to treat rare but deadly severe hematopo…
Sign in to search the full transcript archive, filter by topic, and access every quote from Rachelle Jacques.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans